2-(Tributylstannyl)furan
Product Information
Molecular Formula
C16H30OSn
Molecular Weight
357.12
Description
2-(Tributylstannyl)furan is a specialized chemical utilized as an intermediate in pharmaceutical synthesis, notably in the preparation of antifungal and antibacterial drugs. Its tin content is helpful in boosting the potency of these medications.
Synonyms
tributyl(furan-2-yl)stannane; 2-tributylstannylfuran; tributylstannyl furan; Stannane, tributyl-2-furanyl-; Tributyl(2-furyl)tin; tri-n-butyl(2-furyl)tin; 2-(tri-n-butylstannyl)furan; tributyl(2-furyl)stannane; 2-furyltributyltin; tributylstannylfuran; (tributylstannyl)furan; 2-furyl(tributyl)tin; 2-tributylstannyl-furan; tributyl(2-furanyl)tin; 2-(tnbutylstannyl)furan; tributyl(furan-2-yl)tin; 2-(tributylstannyl)furane
IUPAC Name
tributyl(furan-2-yl)stannane
SMILES
CCCC[Sn](CCCC)(CCCC)C1=CC=CO1
InChI
InChI=1S/C4H3O.3C4H9.Sn/c1-2-4-5-3-13*1-3-4-2/h1-3H3*1,3-4H2,2H3
InChI Key
SANWDQJIWZEKOD-UHFFFAOYSA-N
Boiling Point
90 °C/0.1 mmHg (lit.)
Flash Point
235.4 °F - closed cup
Purity
97%
Density
1.134 g/mL at 25 °C (lit.)
Refractive Index
n20/D 1.494 (lit.)
Safety Information
Hazards
H301 - H312 - H315 - H319 - H372 - H410
Precautionary Statement
P273 - P280 - P301 + P310 - P302 + P352 + P312 - P305 + P351 + P338 - P314
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
1
Rotatable Bond Count
10
Exact Mass
358.131868 g/mol
Monoisotopic Mass
358.131868 g/mol
Topological Polar Surface Area
13.1Ų
Heavy Atom Count
18
Formal Charge
0
Complexity
184
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| CN-112358447-A | Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid | 2020-11-16 |
| WO-2021239117-A1 | Modified proteins and protein degraders | 2020-05-28 |
| US-2021171535-A1 | Tricyclic heterocycles as fgfr inhibitors | 2019-12-04 |
| WO-2021113479-A1 | Tricyclic heterocycles as fgfr inhibitors | 2019-12-04 |
| WO-2021063852-A1 | Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection | 2019-09-30 |
| WO-2020239656-A1 | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis b | 2019-05-29 |
| KR-20220002498-A | Novel indolizine-2-carboxamide active against hepatitis B virus (HBV) | 2019-04-30 |
| WO-2020135771-A1 | Heterocyclic compound intermediate, preparation method therefor and application thereof | 2018-12-29 |
| AU-2019416589-A1 | Heterocyclic compound intermediate, preparation method therefor and application thereof | 2018-12-29 |
| CA-3124898-A1 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | 2018-12-29 |
